Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
72
resultados
Última actualización
27/09/2024 [06:45:00]
Resumen de: EP4434527A1
The present invention provides a novel multi-fused-ring compound and a composition for preventing or treating multiple myeloma comprising the same as an active ingredient. The compound of the present invention is a derivative synthesized from the natural compound ginsenoside as a starting material, and shows no cytotoxicity to normal hematopoietic stem cells while exhibiting a significant killing effect on various multiple myeloma cell lines, indicating that it may be administered for a long period of time without side effects. In addition, the compound of the present invention exhibits a significant synergistic effect when co-administered with the immunomodulator thalidomide or its analog lenalidomide, and thus may be useful as an efficient therapeutic agent or therapeutic aid agent composition for multiple myeloma, an incurable disease.
Resumen de: WO2023086627A1
This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having multiple myeloma (MM). For example, methods and materials that can be used to determine whether or not a mammal (e.g., a human) having MM is likely to develop one or more therapy-related myeloid neoplasms (t-MNs) are provided. This document also relates to methods and materials for treating a mammal (e.g., a human) having MM where the treatment is selected based, at least in part, on whether or not the mammal is likely to develop one or more t-MNs.
Resumen de: US2024309092A1
The present invention generally relates to antibodies that bind to CSF1R and CD3, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease, in particular in the treatment of acute myeloid leukemia (AML).
Resumen de: US2024307396A1
The present disclosure relates to methods for treating celiac disease, especially refractory celiac disease, by administering a therapeutic amount of a JAK inhibitor, or a salt or prodrug thereof, with or instead of gluten-free diet, to a subject in need thereof. Additionally, methods are presented for preventing lymphoma in a subject having or suspected of having celiac disease.
Resumen de: US2024307397A1
A composition for preventing or treating peripheral T-cell lymphoma includes a compound represented by formula 1 or pharmaceutically acceptable salts thereof. Specifically, a pharmaceutical composition based on the composition is capable of effectively ameliorating peripheral T-cell lymphoma by decreasing regulatory T cells and increasing CD8+ T cells. The pharmaceutical composition may exhibit anticancer activity against peripheral T-cell lymphoma by decreasing regulatory T cells which suppress immune responses and increasing CD8+ T cells which exhibit anticancer activity. In addition, the pharmaceutical composition is used for the treatment of peripheral T-cell lymphoma due to excellent safety and tolerability.
Resumen de: US2024307480A1
The present invention relates to a particularly advantageous new therapeutic use of melflufen (melphalan flufenamide; L-melphalanyl-4-fluoro-L-phenylalanine ethyl ester), or a salt thereof: in the treatment or prophylaxis of multiple myeloma in a patient having multiple myeloma who:—has not received a stem cell transplant; or—has received a stem cell transplant that was at least 5 years ago; or—is 75 years old or older; or—has not received a stem cell transplant and is 75 years old or older, or has received a stem cell transplant that was at least 5 years ago and is 75 years old or older; or—has received a stem cell transplant and the disease subsequently progressed at least 36 months after the transplant. The inventors have found that melflufen, and in particular melflufen in combination with dexamethasone, is surprisingly effective for the treatment or prophylaxis of multiple myeloma in these patients. More particularly, the present inventors have found that melflufen demonstrates superior anti-neoplastic activity in comparison to other treatments for multiple myeloma in these patient populations.
Resumen de: US2024307489A1
The present invention refers to a method for treating Notch signaling-dependent disease in the subject with a LRP1 specific inhibitor. The Notch signaling-dependent disease is selected from leukemia. Also provided is a method for screening a drug treating Notch signaling-dependent disease using LRP1 as a target.
Resumen de: US2024309031A1
Compounds of the formula Iwherein X is a bond or —CH2, and pharmaceutically acceptable salts thereof are useful in the parenteral treatment of leukemia, myelodysplastic syndrome or lymphoma, especially in patients presenting with cytarabine resistance and/or over 60 years of age.
Resumen de: US2024307373A1
The present disclosed invention provides pharmaceutical compositions and methods of use for bisbenzylisoquinolines such as 6,6′,7,12-tetramethoxy-2,2′-dimethyl-berbaman, and analogs, derivatives, isomers, and modified forms such as crystalline, salt forms, or a salt of this compound with a pharmaceutically acceptable acid or in combination with other agents to treat acute, chronic and pre-leukemic conditions as well as lymphomas and solid tumors. These include preneoplastic and neoplastic diseases and solid tumors including but not limited to acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), atypical chronic myeloid leukemia (aCML), and acute myeloid leukemia (AML), polycythemia vera (PV), chronic lymphoblastic leukemia (CLL), myeloproliferative syndrome (MPS), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), myelofibrosis (MF), and polycythemia vera (PV).
Resumen de: US2024307335A1
Disclosed herein are methods and compositions relating to the resistance of adoptive immunotherapy caused by the induction of iNOS in tumor associated macrophage. In one aspect, disclosed herein are methods of methods of treating, inhibiting, reducing, decreasing, ameliorating, and/or preventing a cancer and/or metastasis (such as, for example large B cell lymphoma) in a subject comprising administering to the subject an adoptive immune cell immunotherapy (including, but not limited to administration of chimeric antigen receptor (CAR) T cells, CAR natural killer (NK) cells, tumor infiltrating lymphocytes (TILs)) and an agent that blocks dysregulation of the citric acid cycle (such as, for example, an agent that inhibits inducible nitric oxide synthase (iNOS) and/or an agent that inhibits immune responsive gene 1 (IRG1)) or administering to the subject an adoptive immune cell immunotherapy (including, but not limited to administration of chimeric antigen receptor (CAR) T cells, CAR natural killer (NK) cells, tumor infiltrating lymphocytes (TILs)) wherein the immune cell has been modified to disrupt expression of IRG1.
Resumen de: US2024309109A1
The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.
Resumen de: WO2024192139A1
Provided herein are methods for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, and/or CBL mutation; and (b) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody. The subject may have a RAS pathway mutation or a RAS pathway mutation and at least one TET2 mutation identified in the tumor cells. The methods further comprise administering a therapeutically effective amount of a hypomethylating agent. Also provided herein are methods for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, and/or CBL mutation; and (b) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody lenzilumab and a therapeutically effective amount of a hypomethylating agent. The subject may have a RAS pathway mutation or a RAS pathway mutation and at least one TET2 mutation identified in the tumor cells. A therapeutically effective amount of a hypomethylating agent is further administered according to the provided methods.
Resumen de: US2024309079A1
Provided herein are methods for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, and/or CBL mutation; and (b) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody. The subject may have a RAS pathway mutation or a RAS pathway mutation and at least one TET2 mutation identified in the tumor cells. The methods further comprise administering a therapeutically effective amount of a hypomethylating agent. Also provided herein are methods for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, and/or CBL mutation; and (b) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody lenzilumab and a therapeutically effective amount of a hypomethylating agent. The subject may have a RAS pathway mutation or a RAS pathway mutation and at least one TET2 mutation identified in the tumor cells. A therapeutically effective amount of a hypomethylating agent is further administered according to the provided methods.
Resumen de: WO2024183818A1
Use of an anti-CD20 antibody-drug conjugate in the preparation of a drug for treating NHL. The drug has a good clinical curative effect and safety in treating recurrent or refractory NHL after at least two standard treatments.
Resumen de: WO2024183817A1
The use of an anti-CD20 antibody-drug conjugate in the preparation of a drug for treating mantle-cell lymphoma. The drug has good clinical efficacy in treating relapsed or refractory mantle-cell lymphoma, is safe and controllable, and meets clinical requirements that are not met at present.
Resumen de: US2024299558A1
Proteolysis-targeting chimeras (PROTACs) and chimeric compounds that inhibit B-Cell Lymphoma-2 (Bcl-2) protein, and methods of using the same, are provided for treating disease.
Resumen de: US2024299349A1
The present invention provides compounds for use in the treatment or prevention of leukaemia which are based on a 2-amino-1,1′-biphenyl or corresponding carbazole scaffold, in particular, it provides the following compounds of formula (I), their stereoisomers, and their pharmaceutically acceptable salts for use in such treatment: (I) (I) wherein: Y is selected from C=0 and —CR9 (in which R9 is H, —OH or —O-alkyl, (e.g., —O—C1-6 alkyl)); Z is selected from C=0 and —CR10 (in which R10 is H, —OH, —O-alkyl, (e.g., —O—C1-4 alkyl) or —O—C(O)RA wherein RA is H or alkyl (e.g. C1-4 alkyl)); R1 is —NO2 or —NR11R12 (wherein R11 and R12 are both H, or R11 is H and R12 is a group of the formula —C(O)RA in which RA is H or alkyl (e.g. C1-6 alkyl)); each of R2, R4, and R6 to R8 are independently selected from H, alkyl (e.g. C1-6 alkyl), —O-alkyl (e.g. —O—C1-6 alkyl), and halogen; R3 and R5 are independently selected from H, —O-alkyl (e.g. —O—C1-6 alkyl), and halogen; or R1 and R8 together form a group NR13 (in which R13 is H, alkyl (e.g. C1-6 alkyl), or a group of the formula —C(O)RA in which RA is H or alkyl (e.g. G1-6 alkyl)); and represents an optional bond between two adjacent carbon atoms in the ring; with the proviso that when Y and Z are both C═O, and R1 and R8 together form a group NR13, at least one of R2 and R3 is other than H or —CH3. Such compounds find particular use in the treatment or prevention of chronic myeloid leukaemia (G
Resumen de: US2024299411A1
The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof in combination with a composition comprising one or more B-cell leukemia/lymphoma-2 (Bcl-2) family inhibitors. The present invention also provides methods of treating, suppressing, or inhibiting a hyperproliferative disorder or inhibiting tumor growth in subjects by administering compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof and a second composition comprising one or more Bcl-2 family inhibitors.
Resumen de: US2024302374A1
The spectrographic detection of acute leukemia provides for the early detection of acute leukemia, distinguishing between normal blood and blood infected by either Acute Lymphoblastic Leukemia (ALL) or blood infected by Acute Myeloid Leukemia (AML). The spectrographic detection of acute leukemia also provides an alternative method for monitoring the progress of treatment for acute leukemia. The method uses fluorescence spectroscopy techniques, including fluorescence emission spectra (FES) of acetone extracts of red blood cells, synchronous fluorescence emission spectra (SFES) and synchronous fluorescence excitation spectra (SFXS) of different biomolecules found in blood plasma, and comparing ratios of the intensities obtained at certain wavelength peaks.
Resumen de: US2024298618A1
The present disclosure relates to an upstream of mTORC2 (UT2) gene-deficient mouse model and a method of screening therapeutic agents for myeloid leukemia using the same, wherein it was found that the onset of myeloid leukemia and proliferation of myeloid leukemia cells were more facilitated in UT2 gene-deficient mice and UT2 genetic scissor (Cripsr/Cas9)-deficient myeloid leukemia cell lines. In addition, it was found that the survival rate of patients with low expression of UT2 was low in myeloid leukemia patients, while expression of UT2 was low in cells of actual myeloid leukemia patients.
Resumen de: US2024301025A1
Provided are TCRs (e.g., TCRs that bind to MLL, e.g., TCRs that bind to an MLL phosphopeptide, e.g., TCRs that bind to an MLL phosphopeptide/MHC complex), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.
Resumen de: US2024300950A1
Described herein is N-4-4-(4-morpholinyl)-7H-pyrrolo2,3-dpyrimidin-6-ylphenyl-4-3(R)-(1-oxo-2-propen-1-yl)amino-1-piperidinylmethyl-2-pyridinecarboxamide (Compound A) (Formula I),including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.
Resumen de: US2024301078A1
Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).
Resumen de: US2024301082A1
Provided herein are, inter alia, methods for treating oncovirus-positive cancers using anti-CD73 compounds, such as anti-CD73 antibodies. Exemplary oncovirus include human papilloma virus, hepatitis, cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, human herpes virus-8, polyomavirus, adenovirus, human T-cell leukemia virus, and the like.
Nº publicación: US2024301065A1 12/09/2024
Solicitante:
VISTERRA INC [US]
Visterra, Inc
Resumen de: US2024301065A1
Antibody molecules that specifically bind to CD138 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.
BOPI
Sede Electrónica
